CLAIMS

1. Use of a compound of formula I in the manufacture of a medicament for reducing adiposity, treating obesity or treating diabetes in a subject, wherein said medicament is to be administered to said subject at a therapeutically effective amount:



I.

2. The use according to claim 1 wherein said compound is in the form of a salt.

3. The use according to claim 2 wherein the salt is a methanesulfonic acid salt.

4. The use according to claim 1 wherein said subject is a human and said therapeutically effective amount is from 2 to 6 mg/kg/day.

5. The use according to claim 1 wherein said compound is >90% e.e. of the (2a*S*,4*S*,6a*S*,6b*S*,8a*S*,8b*S*,11a*S*,12a*S*,12b*R*) enantiomer.

6. The use according to claim 1 wherein the compound of formula I is to be administered as a salt having formula Ia:



Ia

wherein X is a pharmaceutically acceptable anion.

7. The use according to claim 6 wherein X is Cl^- or $CH_3SO_3^-$.

8. The use according to claim 1, wherein the medicament is for reducing adiposity.

9. The use according to claim 8, wherein the medicament is for reducing adiposity wherein the subject is suffering from, or at risk of, obesity.

10. The use according to claim 1 wherein the subject is suffering from, or at risk of, diabetes.

11. The use according to claim 10 wherein the diabetes is type 2 diabetes.

12. The use according to any of claims 1 to 11 wherein the compound is to be administered orally.

13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula Ia:



Ia

wherein X is methanesulfonate.

14. The pharmaceutical composition according to claim 13 wherein the composition is suitable for oral administration.

15. The pharmaceutical composition according to claim 14 in the form of a tablet or capsule.

16. The pharmaceutical composition according to claim 14 in the form of a solution or suspension.